Skip to main content
. 2022 Feb 18;10(2):486. doi: 10.3390/biomedicines10020486

Figure 3.

Figure 3

Cytotoxicity of modified Tripalm-NPs-PTX with MAC, OEG and β-CD. Cell viability (%) of breast cancer MCF7 cells (A), corresponding normal cells MCF-10A (B), lung cancer A549 cells (C) and non-tumor cells L132 (D), after treatment with modified Tripalm-NPs-PTX and free PTX. Data represent the mean value ± SD of quadruplicate cultures. (*) Significant differences (p < 0.001) between free PTX and modified Tripalm-NPs-PTX. Reprinted from [85] with permission.